VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center / 대한혈액학회지
Korean Journal of Hematology
;
: 138-144, 2008.
Article
in English
| WPRIM
| ID: wpr-720519
ABSTRACT
BACKGROUND:
Treatment of T-cell lymphoblastic lymphoma (T-LBL) with CHOP or CHOP-like chemotherapy has resulted in poor long-term outcomes. High-dose chemotherapy followed by ASCT has been applied for this dreaded disease. However, the efficacy is still controversial. T-LBL is considered the nodal/extranodal presentation of acute lymphoblastic leukemia. Favorable results with VPDL chemotherapy have been reported in the setting of adult lymphoblastic leukemia. We, therefore, treated T-LBL patients with modified VPDL chemotherapy and compared the outcomes with those achieved using upfront ASCT.METHODS:
We retrospectively reviewed the outcomes of 24 T-LBL patients treated either with upfront ASCT (n=11) or VPDL chemotherapy without ASCT (n=13) between January 1996 and October 2005.RESULTS:
The median follow-up duration for surviving patients was 17 months (range, 5~109 months). The two-year event-free survival (EFS) rates were 83.1% in the VPDL group and 27.3% in the upfront ASCT group (P=0.008). The two-year overall survival (OS) rates were 83.9% in the VPDL group and 27.3% in the upfront ASCT group (P=0.006).CONCLUSION:
This study suggests that VPDL chemotherapy is very effective and may be superior to upfront ASCT in the treatment of T-LBL patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Stem Cells
/
T-Lymphocytes
/
Retrospective Studies
/
Follow-Up Studies
/
Disease-Free Survival
/
Stem Cell Transplantation
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
Language:
English
Journal:
Korean Journal of Hematology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS